A Feasibility Study Showing [⁶⁸Ga]Citrate PET Detects Prostate Cancer.

ABSTRACT:

Purpose

The management of advanced or recurrent prostate cancer is limited in part by the lack of effective imaging agents. Metabolic changes in prostate cancer have previously been exploited for imaging, culminating in the recent US FDA approval of [¹¹C]choline for the detection of subclinical recurrent disease after definitive local therapy. Despite this milestone, production of [¹¹C]choline requires an on-site cyclotron, limiting the scope of medical centers at which this scan can be offered. In this pilot study, we tested whether prostate cancer could be imaged with positron emission tomography (PET) using [⁶⁸Ga]citrate, a radiotracer that targets iron metabolism but is produced without a cyclotron.

Procedures

Eight patients with castrate

SUBMITTER: Behr SC 

PROVIDER: S-EPMC6430569 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature